LONDON, England, Oct. 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

* 62% confirmed objective response rate and 12.2-month median duration of response in phase Ib trial

* 11.1-month median progression-free survival in a difficult-to-treat setting

* Five pivotal phase III studies now underway acros . . .

Click here for more information about our products